Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IVDs SHOULD BE VALIDATED IN GROUPS BY LIKE FORMULATION

This article was originally published in The Gray Sheet

Executive Summary

IVDs SHOULD BE VALIDATED IN GROUPS BY LIKE FORMULATION, rather than individually, when assessing a product's accuracy, purity and specificity, the Health Industry Manufacturers Association suggests in April 8 comments on the final draft of FDA's "Guideline for the Manufacture of In Vitro Diagnostic Products." Noting that the latest draft requires prospective validation of each new in vitro diagnostic product, HIMA says the guideline "does not recognize the fact that many formulations are identical in the way that they support (or inhibit) microbial growth."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel